Meg alexander takes on expanded role as president and coo at ovid therapeutics, strengthening leadership for future growth

New york, sept. 11, 2024 (globe newswire) -- ovid therapeutics inc. (nasdaq: ovid), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the promotion of meg alexander to president and chief operating officer (coo). alexander will work in collaboration with ovid's leadership team to advance ovid's development pipeline of potential disease-halting neurotherapeutics and define and execute its go-forward strategy.
COO Ratings Summary
COO Quant Ranking